|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han DH, Choi GH, Kim KS, Choi JS, Park YN,
Kim SU, Park JY, Ahn SH and Han KH: Prognostic significance of the
worst grade in hepatocellular carcinoma with heterogeneous
histologic grades of differentiation. J Gastroenterol Hepatol.
28:1384–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kishi Y, Shimada K, Nara S, Esaki M and
Kosuge T: Role of hepatectomy for recurrent or initially
unresectable hepatocellular carcinoma. World J Hepatol. 6:836–843.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ and
Wu F: Solitary large hepatocellular carcinoma: A specific subtype
of hepatocellular carcinoma with good outcome after hepatic
resection. Ann Surg. 249:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou YM, Zhang XF, Yu F, Liu XB, Wu LP, Li
B and Yang JM: Efficacy of surgical resection for pulmonary
metastases from hepatocellular carcinoma. Med Sci Monit.
20:1544–1549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Bo L, Zhao X and Chen Q:
MicroRNA-133a inhibits cell proliferation, colony formation
ability, migration and invasion by targeting matrix
metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep.
11:3900–3907. 2015.PubMed/NCBI
|
|
9
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan X, Hu J, Wang Y, Gao J, Peng D and
Xia L: MicroRNA-145: A promising biomarker for hepatocellular
carcinoma (HCC). Gene. 541:67–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen J and Hung MC: Signaling-mediated
regulation of MicroRNA processing. Cancer Res. 75:783–791. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xue J, Niu J, Wu J and Wu ZH: MicroRNAs in
cancer therapeutic response: Friend and foe. World J Clin Oncol.
5:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li B, Liu L, Li X and Wu L: miR-503
suppresses metastasis of hepatocellular carcinoma cell by targeting
PRMT1. Biochem Biophys Res Commun. 464:982–987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen
S, Wu Q, Chen C and Wang Z: MiR-125b regulates
epithelial-mesenchymal transition via targeting Sema4C in
paclitaxel-resistant breast cancer cells. Oncotarget. 6:3268–3279.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan HF, Li XQ, Hu HY, Li YC, Cai Z, Mei
XS, Yu P, Nie LP, Zhang W, Yu ZD and Nie GH: Functional elucidation
of miR-494 in the tumorigenesis of nasopharyngeal carcinoma. Tumour
Biol. 36:6679–6689. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu M, Zhi Q, Wang W, Zhang Q, Fang T and
Ma Q: Up-regulation of miR-592 correlates with tumor progression
and poor prognosis in patients with colorectal cancer. Biomed
Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oberg AL, French AJ, Sarver AL,
Subramanian S, Morlan BW, Riska SM, Borralho PM, Cunningham JM,
Boardman LA, Wang L, et al: miRNA expression in colon polyps
provides evidence for a multihit model of colon cancer. PLoS One.
6:e204652011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim J, Lim NJ, Jang SG, Kim HK and Lee GK:
miR-592 and miR-552 can distinguish between primary lung
adenocarcinoma and colorectal cancer metastases in the lung.
Anticancer Res. 34:2297–2302. 2014.PubMed/NCBI
|
|
24
|
Irmady K, Jackman KA, Padow VA, Shahani N,
Martin LA, Cerchietti L, Unsicker K, Iadecola C and Hempstead BL:
Mir-592 regulates the induction and cell death-promoting activity
of p75NTR in neuronal ischemic injury. J Neurosci. 34:3419–3428.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation
of miRNA-452 is associated with adriamycin-resistance in breast
cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Werner H and LeRoith D: The role of the
insulin-like growth factor system in human cancer. Adv Cancer Res.
68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
28
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX,
Miao DS and De W: Lentivirus-mediated RNAi knockdown of
insulin-like growth factor-1 receptor inhibits growth, reduces
invasion, and enhances radiosensitivity in human osteosarcoma
cells. Mol Cell Biochem. 327:257–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang YH, Han XD, Qiu Y, Xiong J, Yu Y,
Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased
expression of insulin-like growth factor-1 receptor is correlated
with tumor metastasis and prognosis in patients with osteosarcoma.
J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scharf JG and Braulke T: The role of the
IGF axis in hepatocarcinogenesis. Horm Metab Res. 35:685–693. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ge YY, Shi Q, Zheng ZY, Gong J, Zeng C,
Yang J and Zhuang SM: MicroRNA-100 promotes the autophagy of
hepatocellular carcinoma cells by inhibiting the expression of mTOR
and IGF-1R. Oncotarget. 5:6218–6228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tanaka S and Arii S: Molecular targeted
therapies in hepatocellular carcinoma. Semin Oncol. 39:486–492.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ulanet DB, Ludwig DL, Kahn CR and Hanahan
D: Insulin receptor functionally enhances multistage tumor
progression and conveys intrinsic resistance to IGF-1R targeted
therapy. Proc Natl Acad Sci USA. 107:10791–10798. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu J and Zhu AX: Targeting insulin-like
growth factor axis in hepatocellular carcinoma. J Hematol Oncol.
4:302011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang B, Wang H and Yang Z: MiR-122
inhibits cell proliferation and tumorigenesis of breast cancer by
targeting IGF1R. PLoS One. 7:e470532012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lian HW, Zhou Y, Jian ZH and Liu RZ:
MiR-323-5p acts as a tumor suppressor by targeting the insulin-like
growth factor 1 receptor in human glioma cells. Asian Pac J Cancer
Prev. 15:10181–10185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li LH, Gao Q, Wang XY and Guo ZJ: miR-378
suppresses HBV-related hepatocellular carcinoma tumor growth by
directly targeting the insulin-like growth factor 1 receptor.
Zhonghua Gan Zang Bing Za Zhi. 21:609–613. 2013.(In Chinese).
PubMed/NCBI
|
|
40
|
Xu W, Hang M, Yuan CY, Wu FL, Chen SB and
Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by
targeting insulin-like growth factor 1 receptor in human non-small
cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870.
2015.PubMed/NCBI
|
|
41
|
Chen C, Zhao Z, Liu Y and Mu D:
microRNA-99a is downregulated and promotes proliferation, migration
and invasion in non-small cell lung cancer A549 and H1299 cells.
Oncol Lett. 9:1128–1134. 2015.PubMed/NCBI
|
|
42
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang LK, Hsiao TH, Hong TM, Chen HY, Kao
SH, Wang WL, Yu SL, Lin CW and Yang PC: MicroRNA-133a suppresses
multiple oncogenic membrane receptors and cell invasion in
non-small cell lung carcinoma. PLoS One. 9:e967652014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yuan Y, Shen Y, Xue L and Fan H: miR-140
suppresses tumor growth and metastasis of non-small cell lung
cancer by targeting insulin-like growth factor 1 receptor. PLoS
One. 8:e736042013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qian X, Yu J, Yin Y, He J, Wang L, Li Q,
Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor
growth and angiogenesis and sensitizes chemosensitivity to
oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
